Skip to content
Markets News
Earnings1 min read

Dr. Reddy’s Q2 profit falls 36% as revenue slips

Makkler Newsroom
October 24, 2026 · Based on reporting by The Economic Times

The company welcomed India’s cap on margins for 137 cancer drugs and outlined plans to relaunch its semaglutide brand.

Key takeaways

  • Second-quarter revenue fell 1.5% to ₹8,671 crore.
  • Profit after tax dropped 36% to ₹925 crore.
  • Dr. Reddy’s expects to relaunch its semaglutide brand in the third quarter of FY27.

Dr. Reddy’s Laboratories reported second-quarter fiscal 2027 revenue of ₹8,671 crore, down 1.5% from a year earlier. Profit after tax fell 36% to ₹925 crore, compared with ₹1,437 crore the previous year.

The company called the cap on trade margins for 137 anti-cancer drugs a positive move. It said the decision by the National Pharmaceutical Pricing Authority is expected to improve patient access to lifesaving medicines.

Co-chairman and managing director G V Prasad said the company recorded double-digit growth in its base business and EBITDA margins above 20% during the quarter. He said Dr. Reddy’s would focus on its core businesses, productivity and strategic growth platforms.

Company officials expect to relaunch its semaglutide brand in the third quarter of FY27 in India, Canada and 10 other markets. Production had been halted in July, according to the report.

Global Generics CEO M V Ramana said demand for the weight-loss and anti-diabetes drug continues in existing markets, while Chile is among newer markets opening up. He said the company expects more emerging markets to open in the latter part of FY27-28, followed by launches in Europe and the United States.

Dr. Reddy’s also said it moved from ninth to eighth place by market share in India during the quarter. It aims to rank among the top five players in the market.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.